This study is testing a medication called BHV-7000 to see if it can help reduce chronic pain in people with inherited erythromelalgia (IEM). IEM is a condition that causes burning pain, often in the hands and feet. Participants will take either BHV-7000 or a matching placebo (an inactive substance) by mouth once a day. The main goal is to see how much the average maximum pain intensity changes over the last three weeks of each treatment period. To join, you must be between 18 and 75 years old, have a diagnosis of inherited erythromelalgia with a specific genetic change (gain of function NaV1.7 mutation), and not have another specific genetic change (Kv7.2/7.3 gain of function). The study plans to enroll 5 participants, but its current status is unclear.

Study design

This is an interventional study where participants will take either BHV-7000 or a placebo, both blinded (meaning neither you nor your doctor will know which you are taking). It is a Phase 1b study and plans to enroll 5 participants.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

The primary outcome is measured during the last three weeks of each 4-week crossover treatment period, but overall follow-up duration is not specified.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.